Rheumatology cl;inicians get a trial-focused update on secukinumab for relapsing polymyalgia rheumatica during prednisolone taper. It highlights sustained remission, steroid-sparing choices, patient symptoms, fungal infection counselling and the need to separate pure polymyalgia rheumatica from possible giant cell arteritis.

Psoriatic arthritis plus obesity is not only a weight conversation. The trial review separates ACR20 and ACR50 joint response from a composite endpoint driven partly by weight loss, and reminds clinicians to counsel gastrointestinal adverse effects before adding tirzepatide.

New myositis drugs are easy to overread from the headline result alone. This review separates skin response, muscle response, steroid sparing, infection risk, and the unanswered question of where brepocitinib sits beside IVIG and conventional DMARDs.